This Biotech Fund Sold $8 Million, Yet Remains Bullish on Terns
A biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
This paragraph outlines why the index level matters for investors, including potential effects on timing and risk assessment, with a concise takeaway.
24,673 articlesA biotech fund reduced its Terns Pharmaceuticals position by about $8 million last quarter. Despite the sale, the the...
Cruise investors wrestle with Carnival earnings anxiety: good, the push-pull between sunny passenger demand and risin...
A major biotech fund boosted its Erasca stake after a monumental rise. This article unpacks the logic, risks, and tak...
In a pivotal speech, the former chair jerome powell sends a clear message about inflation and political pressure. Inv...
Plug Power recently beat quarterly estimates, but that isn’t a guarantee the stock is safe to buy. This guide breaks ...
Biotech earnings chants are rarely about profits for small developers. This guide explains how to read Celcuity's 202...
A rare two-step upgrade on Intel hints at a shifting AI investment narrative. This article breaks down what it means ...
Turnaround stories can spark excitement, but income-focused investors should seek a true dividend top dog. This artic...
Wake up to a clear, actionable investing briefing. This Thursday reads roundup distills ten essential market themes i...
Palantir's journey has been a roller coaster—massive gains, sharp pulls, and ongoing questions. This guide distills w...
Energy markets move fast, but a 10-year horizon changes the game. This guide helps you identify what best energy stoc...
Berkshire Hathaway buying back stock isn’t just a headline. It reflects how the company views its own value and how i...